Tags : Metastatic Pancreatic Cancer

AstraZeneca and Merck & Co’s Lynparza Receive the US FDA’s

Shots: The approval follows the US FDA Oncologic drugs Advisory Committee (ODAC) on 17 Dec based on P-III POLO trial, which involves assessing of Lynparza tablets (300 mg bid) as maintenance monothx vs. PBO in 154 patients in ratio (3:2) with gBRCAm metastatic pancreatic cancer whose disease had not progressed on at least 16 weeks […]Read More

Halozyme to Discontinue its P-III HALO-301 Study of PEGPH20 for

Shots: Halozyme will discontinue its P-III HALO-301 study evaluating PEGPH20 in combination with gemcitabine and nab-paclitaxel (Abraxane) vs gemcitabine and nab-paclitaxel as a 1L therapy for the treatment of patients with metastatic pancreatic cancer The P-III HALO-301 study results: did not meet its 1EPs of OS (11.2 vs 11.5mos.) as there was a higher response […]Read More

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study

Shots: The P-III SEQUOIA study involves assessing of Pegilodecakin + Folfox (folinic acid, 5-FU, oxaliplatin) vs Folfox as monothx. in 567 patients with metastatic adenocarcinoma of the pancreas with diseases progression on one prior gemcitabine-containing regimen The P-III SEQUOIA study did not meet its 1EPs of overall survival. Lilly gained Pegilodecakin following the acquisition of […]Read More